Curated News
By: NewsRamp Editorial Staff
October 20, 2026
Scinai Immunotherapeutics Reports 300% Surge in CDMO Orders
TLDR
- Scinai Immunotherapeutics grew committed CDMO orders over 300% to $8.1 million, with a U.S. deal potentially exceeding $10 million and runway through late 2027.
- Scinai's CDMO secured $8.1 million in committed orders and $5.3 million in net proceeds, with a U.S. agreement including $5.1 million in base fees and $5.85 million in optional services.
- Scinai Immunotherapeutics advances immunology therapies and CDMO services, aiming to improve patient outcomes while expanding operations and creating jobs in Israel.
- Scinai Immunotherapeutics reported $8.1 million in committed customer orders as of Oct. 20, 2026, up from $1.9 million at year-end 2025, with cash runway to late 2027.
Impact - Why it Matters
The sharp increase in committed CDMO orders and the extended cash runway signal growing customer confidence in Scinai's manufacturing capabilities, which could lead to more stable revenue streams and reduce the need for near-term dilutive financing. For investors, this progress may indicate a turning point in the company's commercial execution and improve the outlook for its immunotherapy platform. The broader biotech industry may view this as evidence that specialized CDMO services remain in demand, potentially benefiting other small-cap CDMOs and their partners.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) CEO Amir Reichman issued a shareholder letter highlighting significant progress in the company's contract development and manufacturing organization (CDMO) business, strengthened liquidity, and an extended operating runway. The company reported approximately $8.1 million in committed customer orders as of October 20, 2026, a more than 300% increase from $1.9 million at year-end 2025. This growth is driven by a new agreement with a U.S.-based biopharmaceutical company that includes approximately $5.1 million in committed base service fees and contemplates up to $5.85 million in additional uncommitted services, bringing the combined potential opportunity to over $10 million, subject to further agreements and project milestones.
Scinai also reported approximately $5.3 million in combined net proceeds from recent equity financings, including a standby equity purchase agreement drawdown and a private placement with warrant exercises. Management estimates that current cash resources and expected customer payments will support operations through late 2027, potentially extending into the third quarter of 2028 if additional project phases are activated and delivered. The company remains focused on expanding its CDMO customer base, improving facility utilization, and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. For the full press release, visit https://ibn.fm/3C1F4. Scinai is a biopharmaceutical company advancing immunology therapies and owns Scinai Biopharma Services Ltd., a CDMO with facilities in Jerusalem and Yavne, Israel. The latest updates are available in the company's newsroom at https://ibn.fm/SCNI. This news was distributed by InvestorWire, a specialized communications platform and part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Reports 300% Surge in CDMO Orders
